According to the 2021 WHO classification [6], the molecular biomarkers characterizing a GB are isocitrate dehydrogenase 1⁄2 (IDH 1-2) status, epidermal growth factor receptor (EGFR) amplification, telomerase reverse transcriptase (TERT) gene mutation, alpha-thalassemia/mental retardation, X-linked protein (ATRX) loss, and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation [6]. This evidence concerns the gene MGMT and alpha thalassemia spectrum.